CRESTONE: Initial Efficacy and Safety of Seribantumab in Solid Tumors Harboring NRG1 Fusions - Episode 3

Duration of Seribantumab Therapy and Depth of Response in the CRESTONE Trial

,

Closing out their review of data from the CRESTONE clinical trial, expert panelists highlight the duration and depth of response with seribantumab therapy.

EP. 1: CRESTONE Trial of Seribantumab in NRG1+ Solid Tumors: Trial Design and Safety Data
EP. 2: CRESTONE Trial of Seribantumab in NRG1+ Solid Tumors: Efficacy Data
Now Viewing
EP. 3: Duration of Seribantumab Therapy and Depth of Response in the CRESTONE Trial
EP. 4: Key Takeaways From the CRESTONE Trial of Seribantumab in NRG1+ Solid Tumors
EP. 5: CRESTONE Trial of Seribantumab in NRG1+ Solid Tumors: Real-World Implications